We are a biopharmaceutical company operating in China and the US, focusing on innovative CAR-T cell therapies for hematomas and solid tumors. Since starting operations in 2014, we have developed a number of new technologies in-house and a product pipeline with global equity to address the major challenges faced by CAR-T cell therapy, such as improving safety, improving the efficacy of solid tumors, and reducing treatment costs. Our product pipeline includes an upgraded version of the all-human BCMACAR-T, the only global potential first-of-its-kind Claudin18.2CAR-T approved by IND, and GPC3CAR-T, a potential global pioneer of its kind. For CAR-T cell therapy, we have obtained a total of 7 IND approvals in China, the United States, and Canada, which is currently the highest number of CAR-T companies in China. Under the leadership of a management team composed of experienced academic experts and industry veterans, we have built an integrated cell therapy platform with internal capabilities covering target discovery, pilot antibody development, clinical research, and commercial-scale production.